Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture

GUEST EDITOR: Jan Thirkettle, Chief Development Officer, Freeline Therapeutics
  • Examining current trends in in-house and outsourced manufacture – where is the cell & gene therapy space heading, and why?
  • Where are the key opportunities to target cost of goods reductions in both cell therapy and gene therapy today? How to capitalise upon them?
  • In process and release testing – how are next-generation analytics driving improvements in product quality and accelerating manufacturing timelines?
  • How to demonstrate comparability with both cell therapy and gene therapy products through the transitions between early clinical, pivotal trial and commercial phases?
  • Continuous manufacture: is it likely to impact the cell & gene therapy space? If so, how and where?
  • Standardisation: what are the critical next steps to further enable cell & gene therapy manufacturing?
  • COMING IN SEPTEMBER 2020
Twitter IconVisit Our Blog